Optimizing the Health
Journey with Precision

icon-white

Our strong relationships with GI clinical researchers began with the introduction of innovative diagnostic tools that have helped physicians manage the IBD patient journey. These key relationships, along with our GI Biobank, advanced data mining and data science techniques support us in the development of breakthrough diagnostic tools that help patients and physicians from diagnosis, through disease progression, therapy selection and monitoring.

Diagnostic Pipeline

Enabling precision-guided care

Commercialized PredictrPK® CD/UC Guselkumab Therapeutic
Drug Monitoring
Validation CD/UC Infliximab – maintenance Next Gen IBD
Serologies
CD/UC Infliximab – induction IBD PrecisTM CD/UC Risankizumab Precision-Guided
Biologic Dosing Optimization
CD/UC Adalimumab CD/UC Vedolizumab CD/UC Ustekinumab IBD/CD/UC Anser® MASLD/MASH FIBROSpect® Program Population Assay Feasibility Development Validation Respondr® Anti-TNF Response
Profiling & Selection
CD/UC Infliximab / Adalimumab Next Gen
Monitr®
CD/UC